Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Micron Technology, Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Micron Technology, Inc. trades at $881.63 (market cap $1.03T). The key difference: Micron Technology, Inc. is far larger — about 1053.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Micron Technology, Inc. pays a 0.07% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Micron Technology, Inc. for 49 Days on average.
| MRVI | MU | |
|---|---|---|
Market Cap | $977.37M | $1.03T |
Volume | 2,742,564 | 27,296,988 |
Sector | Health | Technology |
52-Week High | $9.00 | $1.21K |
52-Week Low | $2.83 | $191.94 |
Typical Hold Time | 0 Days | 49 Days |
Enterprise Value | $1.08B | $996.01B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Micron Technology (MU) trades at $953.19, down 3.62% on the day, amid strong fundamentals including a P/E of 12.82 and net income margin of 63.8%. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $33.42 exceeding expectations. Technical indicators show a bullish moving average signal but neutral oscillators, with support at $954. Revenue surged to $37.38 billion in 2025, and cash flow from operations reached $17.53 billion, reflecting robust operational performance.
Outlook remains positive driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030. Risks include cyclical memory pricing and potential growth deceleration. Analyst consensus is strongly bullish with an average price target of $1,590, suggesting significant upside. Institutional sentiment supports growth, but investors should monitor competitive pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
